LAS VEGAS, Dec. 20, 2018 /PRNewswire/ -- Digipath, Inc.(OTCQB: DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis and hemp market, is pleased to announce its receipt of ISO 17025:2017 accreditation from Perry Johnson Laboratory Accreditation (PJLA) as Digipath's accreditation body.
In most major countries, ISO/IEC 17025 is the standard of accreditation in order to be deemed technically competent. Laboratory accreditation uses criteria and procedures specifically developed to determine technical competence, thus assuring customers that the testing, calibration and measurement data supplied by the laboratory or inspection service are accurate and reliable.
The International Organization for Standardization and International Electrotechnical Commission (ISO/IEC) specify the general requirements for the competence to carry out tests and/or calibrations, including sampling. ISO 17025:2017 covers testing and calibration performed using standard methods, non-standard methods, and laboratory-developed methods as applicable to all organizations performing laboratory activities, regardless of the number of personnel. The new 2017 standards provided for an update to terminology, process approach, scope, and the concept of risk-based thinking. "Obtaining accreditation under the revised ISO-17025:2017 guidelines was a team effort by Digipath Labs' employees, and is a testament to our commitment to best practices and reliability in testing," stated Cindy Orser, PhD Digipath's Chief Science Officer and Laboratory Director.
With increased regulatory oversight of the cannabis industry on a state by state basis, ISO-17025 accreditation is now a requirement and not an option. "Digipath Labs has now brought its standard of excellence in cannabis testing under the updated ISO-17025:2017 umbrella as we seek to expand our dominance in cannabis testing markets. This is a major step in positioning Digipath as a global leader in testing services," added Todd Denkin, CEO and Founder.
About Digipath, Inc. & Digipath Labs, Inc. Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Information about Forward-Looking Statements This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.